{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-26-000064","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2026-07-27T20:01:09+00:00","discovered_at":"2026-07-27T20:02:00.384879+00:00","generated_at":"2026-07-27T20:02:16.481934+00:00","sec_items":["1.01","1.02","2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Gossamer Bio to submit NDA for seralutinib in PAH in Sep 2026; reacquires worldwide rights from Chiesi","bullets":["FDA Pre-NDA meeting minutes allow NDA submission based on Phase 3 PROSERA plus confirmatory evidence; submission planned for September 2026.","Gossamer reacquired worldwide rights to seralutinib from Chiesi; Chiesi pays $5M to Gossamer, no upfront cash from Gossamer; Gossamer retains majority of global economics.","Preliminary cash, cash equivalents and marketable securities ~$57M as of June 30, 2026.","Stockholders approved convertible note exchange (reduced debt by ~$115.9M) and authorized reverse stock split to support Nasdaq compliance.","If NDA accepted, FDA approval decision possible in Q3 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-26-000064","json":"https://secwatch.observer/filing/0001728117-26-000064.json","markdown":"https://secwatch.observer/filing/0001728117-26-000064.md","text":"https://secwatch.observer/filing/0001728117-26-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811726000064/0001728117-26-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811726000064/goss-20260723.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-27T20:02:16.481934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}